{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:43:28Z","timestamp":1794980608099,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["R2024.171.1"],"award-info":[{"award-number":["R2024.171.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["UL379\/1-1"],"award-info":[{"award-number":["UL379\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-1530\/B05"],"award-info":[{"award-number":["CRC-1530\/B05"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 3110\/1"],"award-info":[{"award-number":["GRK 3110\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1310\/project ID 325931972"],"award-info":[{"award-number":["CRC1310\/project ID 325931972"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-1399\/A01\/C02"],"award-info":[{"award-number":["CRC-1399\/A01\/C02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1310\/project ID 325931972"],"award-info":[{"award-number":["CRC1310\/project ID 325931972"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-1399\/ project ID 413326622"],"award-info":[{"award-number":["CRC-1399\/ project ID 413326622"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1310\/project ID 325931972"],"award-info":[{"award-number":["CRC1310\/project ID 325931972"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-1399\/A01\/C02"],"award-info":[{"award-number":["CRC-1399\/A01\/C02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["497777992"],"award-info":[{"award-number":["497777992"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 3110\/1"],"award-info":[{"award-number":["GRK 3110\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114593"],"award-info":[{"award-number":["70114593"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Stiftung","doi-asserted-by":"publisher","award":["10.21.1.026MN"],"award-info":[{"award-number":["10.21.1.026MN"]}],"id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients.<\/jats:p>","DOI":"10.1038\/s41467-025-66800-x","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T02:25:47Z","timestamp":1765247147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9547-5812","authenticated-orcid":false,"given":"Lydia","family":"Meder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte I.","family":"Orschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle L.","family":"Bouchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahil","family":"Gholamipoorfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia V.","family":"Orschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-9850","authenticated-orcid":false,"given":"Christoph","family":"Kreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Koker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Nill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilayda G.","family":"Kocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Won","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-0717","authenticated-orcid":false,"given":"Leon","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"H\u00e4upl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lisa","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Florin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Gr\u00fcll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0234-7094","authenticated-orcid":false,"given":"Filippo","family":"Beleggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-4786","authenticated-orcid":false,"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1792","authenticated-orcid":false,"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-2169","authenticated-orcid":false,"given":"Johannes","family":"Br\u00e4gelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-9349","authenticated-orcid":false,"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-8035","authenticated-orcid":false,"given":"Nima","family":"Abedpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland T.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"66800_CR1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/JTO.0000000000000570","volume":"10","author":"K Konig","year":"2015","unstructured":"Konig, K. et al. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients. J. Thorac. Oncol. 10, 1049\u20131057 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"66800_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"66800_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"66800_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu, S. V. et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619\u2013630 (2021).","journal-title":"J. Clin. Oncol."},{"key":"66800_CR5","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko, J., Winslow, M. M. & Sage, J. Mechanisms of small cell lung cancer metastasis. EMBO Mol. Med. 13, e13122 (2021).","journal-title":"EMBO Mol. Med."},{"key":"66800_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1158\/0008-5472.CAN-23-1079","volume":"84","author":"JH Ko","year":"2024","unstructured":"Ko, J. H. et al. Small cell lung cancer plasticity enables NFIB-independent metastasis. Cancer Res. 84, 226\u2013240 (2024).","journal-title":"Cancer Res."},{"key":"66800_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"66800_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/333180a0","volume":"333","author":"S Marusic-Galesic","year":"1988","unstructured":"Marusic-Galesic, S., Stephany, D. A., Longo, D. L. & Kruisbeek, A. M. Development of CD4-CD8+ cytotoxic T cells requires interactions with class I MHC determinants. Nature 333, 180\u2013183 (1988).","journal-title":"Nature"},{"key":"66800_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","volume":"42","author":"BY Nabet","year":"2024","unstructured":"Nabet, B. Y. et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell 42, 429\u2013443.e4 (2024).","journal-title":"Cancer Cell"},{"key":"66800_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan, J. M. et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 39, 1479\u20131496.e18 (2021).","journal-title":"Cancer Cell"},{"key":"66800_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s002510050240","volume":"46","author":"M Edidin","year":"1997","unstructured":"Edidin, M., Achilles, S., Zeff, R. & Wei, T. Probing the stability of class I major histocompatibility complex (MHC) molecules on the surface of human cells. Immunogenetics 46, 41\u201345 (1997).","journal-title":"Immunogenetics"},{"key":"66800_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.it.2016.12.004","volume":"38","author":"A Zevini","year":"2017","unstructured":"Zevini, A., Olagnier, D. & Hiscott, J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 38, 194\u2013205 (2017).","journal-title":"Trends Immunol."},{"key":"66800_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli, I. et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell 36, 84\u201399.e8 (2019).","journal-title":"Cancer Cell"},{"key":"66800_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 (2019).","journal-title":"Cancer Discov."},{"key":"66800_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"66800_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nm.1887","volume":"14","author":"H Poeck","year":"2008","unstructured":"Poeck, H. et al. 5\u2019-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14, 1256\u20131263 (2008).","journal-title":"Nat. Med."},{"key":"66800_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s12276-020-0416-y","volume":"52","author":"A Basit","year":"2020","unstructured":"Basit, A. et al. The cGAS\/STING\/TBK1\/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Exp. Mol. Med. 52, 643\u2013657 (2020).","journal-title":"Exp. Mol. Med."},{"key":"66800_CR18","doi-asserted-by":"publisher","first-page":"e1006720","DOI":"10.1371\/journal.ppat.1006720","volume":"13","author":"R Fang","year":"2017","unstructured":"Fang, R. et al. MAVS activates TBK1 and IKKepsilon through TRAFs in NEMO dependent and independent manner. PLoS Pathog. 13, e1006720 (2017).","journal-title":"PLoS Pathog."},{"key":"66800_CR19","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"66800_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"66800_CR21","doi-asserted-by":"crossref","unstructured":"Meder, L. et al. Blocking the angiopoietin-2-dependent integrin beta-1 signaling axis abrogates small cell lung cancer invasion and metastasis. JCI Insight 9, e166402 (2024).","DOI":"10.1172\/jci.insight.166402"},{"key":"66800_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"66800_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"66800_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02014-x","volume":"23","author":"M Xie","year":"2024","unstructured":"Xie, M. et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol. Cancer 23, 115 (2024).","journal-title":"Mol. Cancer"},{"key":"66800_CR25","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","volume":"35","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J. Clin. Oncol. 35, 3823\u20133829 (2017).","journal-title":"J. Clin. Oncol."},{"key":"66800_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"66800_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC Class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401.e8 (2019).","journal-title":"Cancer Cell"},{"key":"66800_CR28","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","volume":"28","author":"JB Hiatt","year":"2022","unstructured":"Hiatt, J. B. et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. Clin. Cancer Res. 28, 4551\u20134564 (2022).","journal-title":"Clin. Cancer Res."},{"key":"66800_CR29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","volume":"17","author":"EM Nguyen","year":"2022","unstructured":"Nguyen, E. M. et al. Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC. J. Thorac. Oncol. 17, 1014\u20131031 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"66800_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360\u2013364 (2017).","journal-title":"Nature"},{"key":"66800_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccr.2010.12.021","volume":"19","author":"J Calbo","year":"2011","unstructured":"Calbo, J. et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19, 244\u2013256 (2011).","journal-title":"Cancer Cell"},{"key":"66800_CR32","doi-asserted-by":"crossref","unstructured":"Augert, A. et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci. Signal. 12, eaau2922 (2019).","DOI":"10.1126\/scisignal.aau2922"},{"key":"66800_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24164-y","volume":"12","author":"N Roper","year":"2021","unstructured":"Roper, N. et al. Notch signaling and efficacy of PD-1\/PD-L1 blockade in relapsed small cell lung cancer. Nat. Commun. 12, 3880 (2021).","journal-title":"Nat. Commun."},{"key":"66800_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature24627","volume":"551","author":"A Blees","year":"2017","unstructured":"Blees, A. et al. Structure of the human MHC-I peptide-loading complex. Nature 551, 525\u2013528 (2017).","journal-title":"Nature"},{"key":"66800_CR35","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","volume":"4","author":"EJ Brea","year":"2016","unstructured":"Brea, E. J. et al. Kinase regulation of human MHC Class I molecule expression on cancer cells. Cancer Immunol. Res. 4, 936\u2013947 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"66800_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","volume":"21","author":"S Wu","year":"2019","unstructured":"Wu, S. et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat. Cell Biol. 21, 1027\u20131040 (2019).","journal-title":"Nat. Cell Biol."},{"key":"66800_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","volume":"4","author":"R Meuwissen","year":"2003","unstructured":"Meuwissen, R. et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4, 181\u2013189 (2003).","journal-title":"Cancer Cell"},{"key":"66800_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00432-024-05942-9","volume":"150","author":"O Ibruli","year":"2024","unstructured":"Ibruli, O. et al. A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. J. Cancer Res. Clin. Oncol. 150, 496 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"66800_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41602-1","volume":"14","author":"V Petrosius","year":"2023","unstructured":"Petrosius, V. et al. Exploration of cell state heterogeneity using single-cell proteomics through sensitivity-tailored data-independent acquisition. Nat. Commun. 14, 5910 (2023).","journal-title":"Nat. Commun."},{"key":"66800_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"66800_CR41","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1074\/mcp.M116.065524","volume":"16","author":"DL Plubell","year":"2017","unstructured":"Plubell, D. L. et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol. Cell Proteom. 16, 873\u2013890 (2017).","journal-title":"Mol. Cell Proteom."},{"key":"66800_CR42","doi-asserted-by":"crossref","unstructured":"Uniform manifold approximation and projection. Nat. Rev. Methods Primers 4, 83 (2024).","DOI":"10.1038\/s43586-024-00369-5"},{"key":"66800_CR43","doi-asserted-by":"crossref","unstructured":"Levine, J. H. et al. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell 162, 184\u2013187 (2015).","DOI":"10.1016\/j.cell.2015.05.047"},{"key":"66800_CR44","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies, J. et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7, e51862 (2012).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66800-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:16:45Z","timestamp":1765282605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66800-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66800"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66800-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C.R. received consulting and lecture fees from Abbvie, Roche, KinSea, Vitis, Cerus, Lilly, Novartis, Takeda, AstraZeneca, Vertex, and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. J.B. has received research funding from Bayer and travel grants by Merck and Bicycle Therapeutics outside of the submitted work. T.O. received research funding from Gilead and Merck KGaA, is a consultant\/received honoraria for\/from Beigene, Roche, Janssen, Merck KGaA, Gilead, Kronos Bio and Abbvie (all not related to this work). The remaining authors declare no conflicting interests. J.B. has received research funding from Bayer outside of the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10983"}}